CompanionDx to Expand NGS Offerings with Thermo Fisher Cancer Assays | GenomeWeb

NEW YORK (GenomeWeb) – CompanionDx, a high-complexity CLIA-certified laboratory, announced on Monday that it will expand its next-generation sequencing (NGS) offerings with two of Thermo Fisher Scientific cancer assays. 

CompanionDx said it will provide the Oncomine Focus Assay and the Oncomine Comprehensive Assay to clients performing studies across a range of different cancer types. The deal creates new NGS services that could be used in combination with pharmacogenomics to facilitate drug development and clinical research program by drug manufacturers, CompanionDx said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.